A US House Veterans' Affairs health subcommittee held a Wednesday hearing on veterans' access to psychedelic-assisted therapies, with VA officials and researchers testifying. The VA's Andrew Gradison said the department is running 21 active clinical studies on psychedelics, including an August-announced psilocybin trial in veterans with treatment-resistant depression.
The House Veterans' Affairs Subcommittee on Health will hold a Wednesday hearing titled "Psychedelic-Assisted Therapies for Veterans: The Path Forward," with VA officials, medical professionals and researchers testifying. A VA official's written testimony says the department is conducting 21 active clinical studies on psychedelics, including a trial announced in August on psilocybin for veterans with treatment-resistant depression.
The US Drug Enforcement Administration has proposed 2027 aggregate production quotas for Schedule I and II controlled substances and an assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine and phenylpropanolamine. Written comments are due by December 10, 2026, under Docket No. DEA-1730P, after which the Administrator will publish a final order.
Australia's Therapeutic Goods Administration has published interim decisions on proposed amendments to the Poisons Standard from ACMS #48, Joint ACMS-ACCS #42 and ACCS #41, and invited comment by 4 December 2026. The notice covers interim decisions only; the amendments are not final.
Officials from HHS, the FDA, the VA and ARPA-H described at The Psychedelic Healthcare Forum on Oct. 15 how an April executive order has reshaped federal preparation for psychedelic medicines. HHS Deputy General Counsel Matt Zorn said the order does not change statutory or regulatory standards, while the VA has designated 10 medical centres as Phase 1 lead sites and estimated around 100,000 veterans would qualify for psychedelic-assisted therapy immediately upon approval. The FDA's Dr Valentina Mantua said the agency oversees approximately 433 Investigational New Drug applications and has already requested REMS proposals from developers, and ARPA-H's Dr Al Bugazia cited cardiotoxicity and QTc prolongation risks, the lack of a domestic GMP manufacturer and a DEA manufacturing quota of just over 200 grams as obstacles for ibogaine research.
Medical providers, veterans, legal experts and the legislative sponsor of New Mexico's Medical Psilocybin Act criticised draft rules 7.35.3 and 7.35.2 NMAC at an Oct. 2 public hearing before the New Mexico Department of Health, arguing the proposed prescriber gateway, landlord consent requirements and staffing ratios exceed the statute and could block access. The department is accelerating the program's launch to December 2026, a year ahead of the statutory deadline. Speakers said the rules would require an in-person exam with a certifying clinician, patient identification cards and up to 30 days of state review, and that landlord sign-off for homebound patients and leased healing centres conflicts with fair housing law; some clinical educators praised the draft training and supervision standards. Sixteen advocacy and clinical organisations have asked Rep. Nathan P. Small to add $500,000 for the Treatment Equity Fund and $500,000 for University of New Mexico palliative research.
The US Food and Drug Administration has issued a request for information on approaches it is considering for the design of early-phase clinical trials of ibogaine drug products, and is seeking public comment.
Why it matters: The request sets out the protocol questions the agency wants answered, including a starting dose cap, so researchers and sponsors can see what evidence the FDA expects before early-phase ibogaine trials proceed.
MAPS attended the FDA's September 14 public hearing on the potential future therapeutic use of psychedelic drugs and plans to submit written testimony on systems readiness.
The U.S. Department of Veterans Affairs launched PIVOT on August 5, a five-site trial of Compass Pathways' COMP360 psilocybin in veterans with treatment-resistant depression.
The TGA has published its interim decisions on proposed amendments to the Poisons Standard considered at ACMS #47 and Joint ACMS-ACCS #40, and invites comment. The closing date for submissions is 10 July 2026. The notice is a summary only and does not list the substances or amendments covered.
Why it matters: The notice marks the interim stage of scheduling, so anyone with an interest in the proposed Poisons Standard amendments has until 10 July 2026 to comment before a final decision.
The TGA has extended the closing date for comment on its interim decision on a proposed amendment to the Poisons Standard concerning psilocybine, from ACMS #47, to 31 July 2026. The interim decision follows the June 2025 advisory committee meeting.
The Advisory Council on the Misuse of Drugs has published an updated review of the use and harms of ketamine, following a commission from the then Minister for Policing, Fire and Crime Prevention in January 2025. The report reviews prevalence and harms of ketamine and its analogues in the UK, describes legitimate uses including treatment and research, covers emerging health harms such as hepatobiliary toxicity, and describes supply and trafficking.
Why it matters: The review was commissioned to advise on ketamine's classification, so its findings on prevalence, hepatobiliary toxicity and supply could shape how the UK schedules the drug and its analogues.
The TGA has published interim decisions on proposed amendments to the Poisons Standard arising from the Advisory Committee on Chemicals Scheduling (ACCS) #40 and the Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (Joint ACMS-ACCS) #39. The notice invites comment, with a closing date of 23 January 2026. The feed gave no further detail on which substances or schedules the interim decisions cover.